Biovica announced that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population. The healthcare provider operates 18 hospitals of which one is a National Cancer Institute (NCI) Comprehensive Cancer Center and has been a partner to Biovica during the clinical development of DiviTum® TKa.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.706 SEK | +6.36% | -22.81% | -33.88% |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.88% | 13.08M | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 377M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica Signs Second Agreement with US Healthcare Provider